Gordon G, Mackow M C, Levy H R
Laboratory for Molecular Pharmacology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Arch Biochem Biophys. 1995 Apr 1;318(1):25-9. doi: 10.1006/abbi.1995.1199.
Previous studies have demonstrated that certain 17- and 20-ketosteroids are potent inhibitors of the NADP-linked oxidation of glucose 6-phosphate by mammalian glucose 6-phosphate dehydrogenases. This inhibition is uncompetitive with respect to both NADP+ and glucose 6-phosphate. In order to elucidate the detailed mechanism of this rare type of inhibition, we examined the effects of steroids on human glucose 6-phosphate dehydrogenase catalyzing the reverse reaction, i.e., the reduction of the gluconolactone by NADPH. To circumvent problems associated with the known instability of 6-phospho-delta-gluconolactone, the natural product of glucose 6-phosphate oxidation, the more stable 6-phospho-gamma-gluconolactone was used. Dehydroepiandrosterone, epiandrosterone, 16 alpha-bromoepiandrosterone, and dehydroepiandrosterone sulfate all inhibited the reverse reaction uncompetitively with respect to both NADPH and the gamma-lactone. The Ki values for each of these steroids, determined by varying either coenzyme or substrate in both the forward and the reverse reactions, are very similar. These results demonstrate that steroids inhibit glucose 6-phosphate dehydrogenase by binding to the ternary enzyme-coenzyme-substrate ternary complex(es). This is the first direct demonstration that uncompetitive inhibition of a two-substrate enzyme, by compounds other than its substrates or products, can occur by binding of the inhibitor to a ternary enzyme complex.
先前的研究表明,某些17-和20-酮类固醇是哺乳动物葡萄糖6-磷酸脱氢酶对NADP偶联的葡萄糖6-磷酸氧化的有效抑制剂。这种抑制作用对NADP⁺和葡萄糖6-磷酸均为非竞争性。为了阐明这种罕见抑制类型的详细机制,我们研究了类固醇对催化逆反应(即由NADPH还原葡糖酸内酯)的人葡萄糖6-磷酸脱氢酶的影响。为了规避与葡萄糖6-磷酸氧化的天然产物6-磷酸-δ-葡糖酸内酯已知的不稳定性相关的问题,使用了更稳定的6-磷酸-γ-葡糖酸内酯。脱氢表雄酮、表雄酮、16α-溴表雄酮和硫酸脱氢表雄酮对NADPH和γ-内酯均以非竞争性方式抑制逆反应。通过在正向和逆向反应中改变辅酶或底物来确定的这些类固醇各自的Ki值非常相似。这些结果表明,类固醇通过与三元酶-辅酶-底物复合物结合来抑制葡萄糖6-磷酸脱氢酶。这是首次直接证明,除底物或产物之外的化合物对双底物酶的非竞争性抑制可通过抑制剂与三元酶复合物结合而发生。